RESUMEN
ABSTRACT: This review summarizes the evaluation for underlying rheumatic conditions in patients presenting with acute pericarditis, treatment considerations for specific rheumatic conditions, and the role of imaging in diagnosis and monitoring. Pericarditis may be one of the initial presentations of a rheumatic disease or identified in a patient with known rheumatic disease. There is also growing evidence for using anti-inflammatory and immunosuppressive agents for treating recurrent pericarditis, which can overlap with the treatment of rheumatic diseases.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Colchicina/uso terapéutico , Pericarditis/tratamiento farmacológico , Enfermedad Aguda , Aspirina/administración & dosificación , Aspirina/uso terapéutico , Proteína C-Reactiva/análisis , Colchicina/administración & dosificación , Manejo de la Enfermedad , Método Doble Ciego , Quimioterapia Combinada , Electrocardiografía , Glucocorticoides/uso terapéutico , Hospitalización , Humanos , Ibuprofeno/uso terapéutico , Inmunosupresores , Masculino , Persona de Mediana Edad , Pericarditis/sangre , Ensayos Clínicos Controlados Aleatorios como Asunto , Recurrencia , Troponina T/sangreAsunto(s)
Ecocardiografía , Cardiopatías Congénitas , Imagen por Resonancia Magnética , Síncope/etiología , Adulto , Femenino , Cardiopatías Congénitas/complicaciones , Cardiopatías Congénitas/diagnóstico por imagen , Cardiopatías Congénitas/patología , Ventrículos Cardíacos/diagnóstico por imagen , Ventrículos Cardíacos/patología , HumanosRESUMEN
Pharmacologic therapy of lipid disorders has become an established means to reduce cardiovascular morbidity and mortality. Compared to middle-aged individuals with hyperlipidemia, the use of such treatment in the elderly population has been controversial, as there is only scant data from large clinical trials that can be applied to this group. Therefore, current recommendations for specific anti-lipid drug use in older individuals must weigh each drug's potential benefits against the potential treatment risks that are inherent to this age group.